Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and Safety of Eliapixant in Refractory Chronic Cough: The Randomized, Placebo-Controlled Phase 2b PAGANINI Study.
Dicpinigaitis PV, Morice AH, Smith JA, Sher MR, Vaezi M, Guilleminault L, Niimi A, Gude K, Krahn U, Saarinen R, Pires PV, Wosnitza M, McGarvey L; PAGANINI Investigators. Dicpinigaitis PV, et al. Among authors: wosnitza m. Lung. 2023 Jun;201(3):255-266. doi: 10.1007/s00408-023-00621-x. Epub 2023 Jun 1. Lung. 2023. PMID: 37261531 Free PMC article. Clinical Trial.
Biomarker analysis from the phase 2b randomized placebo-controlled trial of riociguat in early diffuse cutaneous systemic sclerosis.
Khanna D, Kramer F, Höfler J, Ghadessi M, Sandner P, Allanore Y, Denton CP, Kuwana M, Matucci-Cerinic M, Pope JE, Atsumi T, Bečvář R, Czirják L, De Langhe E, Hachulla E, Ishii T, Ishikawa O, Johnson SR, Riccieri V, Schiopu E, Silver RM, Smith V, Stagnaro C, Steen V, Stevens W, Szücs G, Truchetet ME, Wosnitza M, Distler O. Khanna D, et al. Among authors: wosnitza m. Rheumatology (Oxford). 2024 Mar 9:keae150. doi: 10.1093/rheumatology/keae150. Online ahead of print. Rheumatology (Oxford). 2024. PMID: 38460548
Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial.
Khanna D, Allanore Y, Denton CP, Kuwana M, Matucci-Cerinic M, Pope JE, Atsumi T, Bečvář R, Czirják L, Hachulla E, Ishii T, Ishikawa O, Johnson SR, De Langhe E, Stagnaro C, Riccieri V, Schiopu E, Silver RM, Smith V, Steen V, Stevens W, Szücs G, Truchetet ME, Wosnitza M, Laapas K, de Oliveira Pena J, Yao Z, Kramer F, Distler O. Khanna D, et al. Among authors: wosnitza m. Ann Rheum Dis. 2020 May;79(5):618-625. doi: 10.1136/annrheumdis-2019-216823. Ann Rheum Dis. 2020. PMID: 32299845 Free PMC article. Clinical Trial.
Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): open-label, long-term extension of a phase 2b, randomised, placebo-controlled trial.
Distler O, Allanore Y, Denton CP, Kuwana M, Matucci-Cerinic M, Pope JE, Atsumi T, Bečvář R, Czirják L, Hachulla E, Ishii T, Ishikawa O, Johnson SR, De Langhe E, Stagnaro C, Riccieri V, Schiopu E, Silver RM, Smith V, Steen V, Stevens W, Szücs G, Truchetet ME, Wosnitza M, Laapas K, Kramer F, Khanna D. Distler O, et al. Among authors: wosnitza m. Lancet Rheumatol. 2023 Nov;5(11):e660-e669. doi: 10.1016/S2665-9913(23)00238-2. Lancet Rheumatol. 2023. PMID: 38251533 Clinical Trial.
[Merkel cell carcinoma].
Wosnitza M, Bozkurt A, O'Dey D, Pallua N, Megahed M. Wosnitza M, et al. Hautarzt. 2009 May;60(5):366-8. doi: 10.1007/s00105-009-1748-7. Hautarzt. 2009. PMID: 19381467 German.
[Contact sensitization to azole antimycotics].
Brans R, Wosnitza M, Baron JM, Merk HF. Brans R, et al. Among authors: wosnitza m. Hautarzt. 2009 May;60(5):372-5. doi: 10.1007/s00105-009-1751-z. Hautarzt. 2009. PMID: 19367370 German.
14 results